ReviewOrthopaedic journal of sports medicine2022
Regulatory and Ethical Aspects of Orthobiologic Therapies.
Review in Orthopaedic journal of sports medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Fracture healing: from molecular and cellular mechanisms to therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Orthobiologics in Trauma: Current Trends, Future Directions, and Regenerative Strategies.Cureus · 2026Review
- Mapping awareness and application of orthobiologics among orthopaedic professionals: A cross-sectional study.World journal of orthopedics · 2026Article
- Laws and regulations on platelet-rich plasma use for musculoskeletal pathologies in South America: a narrative review.International orthopaedics · 2026Review
- Advancing Intervertebral Disc Biology via Omics: Implications for Nucleus Pulposus Progenitor Cell-Based Regeneration.JOR spine · 2025Review
- Clinical Efficacy and Risks of Intradiscal Orthobiological Injections: A Narrative Review.Current pain and headache reports · 2025Review
- Evidence-based guidelines on orthobiologics.EFORT open reviews · 2025Article
- The Availability and Pricing of Orthobiologic Knee Injections in the Chicago Metropolitan Area: A Market Assessment Study.Orthopaedic journal of sports medicine · 2025Article
- Cartilage repair: unleashing PRP's potential in organoid models.Cytotechnology · 2025Review
- Orthobiologics Revisited: A Concise Perspective on Regenerative Orthopedics.Current issues in molecular biology · 2025Review
- Innovative Approaches in Knee Osteoarthritis Treatment: A Comprehensive Review of Bone Marrow-Derived Products.Biomedicines · 2024Review
- Enhancing Cartilage Repair: Surgical Approaches, Orthobiologics, and the Promise of Exosomes.Life (Basel, Switzerland) · 2024Review
- Review
- Efficacy of Platelet-Rich Plasma Intra-articular Injections in Hip and Knee Osteoarthritis.Cureus · 2024Review
- Review
- Comparative single-cell transcriptional and proteomic atlas of clinical-grade injectable mesenchymal source tissues.Science advances · 2024Article
- Recent advancements in cartilage tissue engineering innovation and translation.Nature reviews. Rheumatology · 2024Review
- Stable Housekeeping Genes in Bone Marrow, Adipose Tissue, and Amniotic Membrane-Derived Mesenchymal Stromal Cells for Orthopedic Regenerative Medicine Approaches.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orthobiologic therapies show significant promise to improve outcomes for patients with musculoskeletal pathology. There are considerable research efforts to develop strategies that seek to modulate the biological environment to promote tissue regeneration and healing and/or provide symptomatic relief. However, the regulatory pathways overseeing the clinical translation of these therapies are complex, with considerable worldwide variation. The introduction of novel biologic treatments into clinical practice raises several ethical dilemmas. In this review, we describe the process for seeking approval for biologic therapies in the United States, Europe, and Japan. We highlight a number of ethical issues raised by the clinical translation of these treatments, including the design of clinical trials, monitoring outcomes, biobanking, "off-label" use, engagement with the public, marketing of unproven therapies, and scientific integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.